ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041736 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vittoria Cenni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", National Research Council (IGM-CNR), Unit of Bologna, 40136 Bologna, Italy. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms, Muscle Proteins, Nuclear Proteins. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione Cassa di Risparmio in Bologna, FAR 2019 Interdepartmental Grant (University of Modena and Reggio Emilia).
Abstract (Originalsprache)
Ankrd2, a mechanoresponsive protein primarily studied in muscle physiology, is emerging as a player in cancer progression. This study investigates the functional role of Ankrd2 in osteosarcoma cells, revealing its critical involvement in cell proliferation and response to chemotherapeutic drugs. We showed that Ankrd2 knockdown impairs the activation of PI3K/Akt and ERK1/2 pathways, reduces levels of cell cycle regulators including cyclin D1 and cyclin B, and counteracts the expression of nuclear lamin A and lamin B, disrupting nuclear morphology and DNA integrity. Strikingly, the loss of Ankrd2 enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin, highlighting Ankrd2 potential as a therapeutic target to improve chemotherapeutic efficacy. Defining a novel mechanistic role for Ankrd2 in promoting tumor progression, we propose that Ankrd2 reduction could be exploited as an adjuvant strategy to enhance the efficacy of chemotherapy, offering new therapeutic opportunities for OS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", National Research Council (IGM-CNR), Unit of Bologna, 40136 Bologna, Italy.
- IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
- Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
- Group for Muscle Cellular and Molecular Biology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
- Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 41124 Modena, Italy.
ORCID-Profile: Vittoria Cenni, Alberto Bavelloni, Elisabetta Mattioli, Snezana Kojic, Giulia Orlandi, William L Blalock
Förderung
- Fondazione Cassa di Risparmio in Bologna
- FAR 2019 Interdepartmental Grant (University of Modena and Reggio Emilia)
Zitieren
APA
Cenni, V., Bavelloni, A., Capanni, C., Mattioli, E., Bortolozzo, F., Kojic, S., Orlandi, G., Bertacchini, J., & Blalock, W. L. (2025). ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041736
Vancouver
Cenni V, Bavelloni A, Capanni C, Mattioli E, Bortolozzo F, Kojic S, et al. ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041736
BibTeX
@article{Cenni2025,
author = {Cenni, Vittoria and Bavelloni, Alberto and Capanni, Cristina and Mattioli, Elisabetta and Bortolozzo, Federico and Kojic, Snezana and Orlandi, Giulia and Bertacchini, Jessika and Blalock, William L},
title = {ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041736}
}
EUVIMED